Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.

ALX Oncology pivots to targeting HER2-positive underperformance in the intent-to-treat gastric cancer population. See why ...

Researchers found that autistic and non-autistic people move their faces differently when expressing emotions like anger, happiness, and sadness. Autistic participants tended to rely on different ...

In January 2026, ALX Oncology announced topline data from the exploratory analysis conducted to identify biomarkers of response to the evorpacept/zanidatamab combination. These findings show that ...

As key molecules on the surface of immune cells, Fc receptors are the core hub of antibody-mediated effector functions. They play an irreplaceable role in physiological processes such as ...

Creative Biolabs announces upgraded downstream services designed to bridge the gap between raw antibody expression and ...

In this phase 1-2 randomized controlled trial involving adults with myotonic dystrophy type 1, del-desiran was well-tolerated in most patients 2. The treatment was also associated with decreased ...

Promatix Biosciences Ltd (Promatix), an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, today presented positive ...

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity ...

You may know me from the Opinion pages of the print paper, where I have been an editor since 2017. Earlier this year I scrapped with Vice President JD Vance about free markets, which may have caught ...